8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Mar 2, 2026·SEC
GT Biopharma, Inc.(GTBP)Earnings, Financials & Key Ratios
GTBP•NASDAQ
$0.43
Price updated Jun 27, 2026
AboutGT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Show more
- Revenue$0
- EBITDA-$12M+5.6%
- Net Income-$28M-115.4%
- EPS (Diluted)-6.25+9.9%
- ROE-1377.41%-203.8%
GTBP Price & Volume
GT Biopharma, Inc. (GTBP) stock price & volume — 10-year historical chart
Loading chart...
Clinical Stage Pipeline Faces Severe Liquidity Constraints
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
Key Thesis Takeaways
- GT Biopharma remains a high-risk, clinical-stage entity characterized by a persistent lack of commercial revenue and a massive accumulated deficit of $723.9 million as of 2025Q4.
- While the company continues to advance its TriKE immunotherapy platform, the volatility in quarterly operating losses—reaching $5.6 million in 2025Q4—suggests that the current capital structure is insufficient to support long-term development.
- Investors should remain cautious as the company's reliance on external financing to bridge its cash burn creates significant dilution risk and operational uncertainty.
Verdict Logic
the company's $6.8 million cash balance as of 2025Q4, when measured against historical quarterly burn rates, suggests an imminent risk of liquidity exhaustion that likely necessitates further dilutive capital raises.
GTBP Growth Metrics
GT Biopharma, Inc. (GTBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-308.96%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.31%
Return on Capital
10 Years-255.11%
5 Years-325.55%
3 Years-413.04%
Last Year-603.45%
GTBP Recent Earnings
GT Biopharma, Inc. (GTBP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.11-37.5%
$0.08
Rev
—
—
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$2.22-909.1%
$0.22
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.83-118.4%
$0.38
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.55+19.1%
$0.68
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.11vs $0.08-37.5% | — |
| Q2 2026 | Mar 2, 2026 | $2.22vs $0.22-909.1% | — |
| Q4 2025 | Nov 14, 2025 | $0.83vs $0.38-118.4% | — |
| Q3 2025 | Aug 14, 2025 | $0.55vs $0.68+19.1% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for GT Biopharma, Inc. (GTBP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.43 | $4.57M | -0.07 | — | — | -1377.41% | 9.66% | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $0.31 | $60.51M | -0.54 | -13.43% | -299.66% | — | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $1.02 | $129.73M | -0.91 | 14.85% | -173.02% | — | — |
Compare GTBP vs Peers
GT Biopharma, Inc. (GTBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GTBP SEC Filings & Documents
GT Biopharma, Inc. (GTBP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GTBP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GTBP Frequently Asked Questions
GT Biopharma, Inc. (GTBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GTBP profitable?
GT Biopharma, Inc. (GTBP) reported a net loss of $47.7M for fiscal year 2025.
Dividend & Returns
Does GTBP pay dividends?
Yes, GT Biopharma, Inc. (GTBP) pays a dividend with a yield of 9.66%. This makes it attractive for income-focused investors.
What is GTBP's return on equity?
GT Biopharma, Inc. (GTBP) has a return on equity (ROE) of -1377.4%. Negative ROE indicates the company is unprofitable.
What is GT Biopharma, Inc.'s free cash flow?
GT Biopharma, Inc. (GTBP) had negative free cash flow of $13.2M in fiscal year 2025, likely due to heavy capital investments.